CapsoVision Stock Edges Higher as FDA AI Decision Becomes the Real Test
CapsoVision shares rose 0.8% to $6.67 in late morning trading Wednesday, bucking a 1.4% drop in the medical-device sector. No new company news was released; investors focused on pending FDA clearance for its AI-assisted reading tool and a planned third-quarter colon-capsule filing. First-quarter revenue held steady at $2.8 million, while gross margin slipped to 48% amid higher costs.